Table 3.
Trade name | Company | Nonproprietary name | Type | SNARE target | Preparation | Storage temperature | Units per vial | US FDA approved indications for dystonia (year approved) |
---|---|---|---|---|---|---|---|---|
Botox | Allergan, Irvine, CA, USA | OnabotulinumtoxinA | A | SNAP25 | Powder | <8 °C | 50, 100, 200 | Blepharospasm (1989); cervical dystonia (2000) |
Dysport | Ipsen, Slough, UK | AbobotulinumtoxinA | A | SNAP25 | Powder | <8 °C | 300, 500 | Cervical dystonia (2009) |
Xeomin | Merz Pharmaceuticals, Greensboro, NC, USA | IncobotulinumtoxinA | A | SNAP25 | Powder | <25 °C | 50, 100 | Blepharospasm; cervical dystonia (2010) |
Myobloc | US World Meds, Louisville, KY, USA | RimabotulinumtoxinB | B | VAMP | Solution | <8 °C | 2500, 5000, 10,000 | Cervical dystonia (2000) |
SNARE = soluble N-ethylmaleimide-sensitive factor attachment receptor proteins; SNAP = soluble N-ethylmaleimide sensitive fusion protein (NSF) attachment protein; VAMP = vesicle-associated membrane protein; FDA = Federal Drug Administration